Global Prostate Cancer Testing Market Growth (Status and Outlook) 2023-2029

Global Prostate Cancer Testing Market Growth (Status and Outlook) 2023-2029

Prostate cancer testing refers to the tests conducted for the detection, localization, grading, and staging of prostate carcinoma. The currently established methods of prostate cancer detection include digital rectal examination (DRE), serum prostate-specific antigen (PSA) tests, and transrectal ultrasound (TRUS)-guided prostate biopsy using a systematic 12-core method.

LPI (LP Information)' newest research report, the “Prostate Cancer Testing Industry Forecast” looks at past sales and reviews total world Prostate Cancer Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Testing sales for 2023 through 2029. With Prostate Cancer Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Testing industry.

This Insight Report provides a comprehensive analysis of the global Prostate Cancer Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Testing.

The global Prostate Cancer Testing market size is projected to grow from US$ 13140 million in 2022 to US$ 22410 million in 2029; it is expected to grow at a CAGR of 7.9% from 2023 to 2029.

The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it. Based on these statistics, we can see that the prevalence rate of prostate cancer is increasing across the world and hence, it is driving the market.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Testing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
PSA Tests
CTC Tests
Immunohistochemistry
PCA3 Tests
Others

Segmentation by application
Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Genomic Health
OPKO
Siemens Healthcare
DiaSorin
bioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics

Please note: The report will take approximately 2 business days to prepare and deliver.